Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders are probably feeling a little disappointed, since its shares fell 8.5% to US$46.00 in the week after its latest full-year results. Revenues came in 29% better than analyst models expected, at US$18mwhile statutory losses per share were US$5.26, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Cytokinetics

Taking into account the latest results, the current consensus from Cytokinetics' 17 analysts is for revenues of US$32.3m in 2025. This would reflect a huge 75% increase on its revenue over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$5.74. Before this latest report, the consensus had been expecting revenues of US$47.8m and US$5.33 per share in losses. There's been a definite change in sentiment in this update, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.

The average price target was broadly unchanged at US$79.10, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Cytokinetics analyst has a price target of US$120 per share, while the most pessimistic values it at US$60.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. For example, we noticed that Cytokinetics' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 75% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 12% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 20% per year. So it looks like Cytokinetics is expected to grow faster than its competitors, at least for a while.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. They also downgraded Cytokinetics' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target held steady at US$79.10, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Cytokinetics going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for Cytokinetics (1 can't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.